|drug870||Control (albumin 5%) Wiki||1.00|
|drug886||Convalescent Plasma (anti-SARS-CoV-2 plasma) Wiki||0.71|
|D003095||Collagen Diseases NIH||0.33|
|D012216||Rheumatic Diseases NIH||0.30|
There is one clinical trial.
SAR-COVID is a national, multicenter, prospective, observational longitudinal registry of consecutive patients with diagnosis of rheumatic diseases treated or not with immunomodulatory and/or immunosuppressive drugs and SARS-CoV-2 infection (asymptomatic or COVID-19). Hypothesis: Patients with rheumatic diseases who are under chronic treatment with immunomodulatory and/or immunosuppressive drugs more frequently have an asymptomatic infection, a milder COVID-19 and lower mortality than patients with rheumatic diseases without immunomodulatory and/or immunosuppressive treatments.
Description: Death caused by SARS-CoV-2 infectionMeasure: Mortality Time: 2 month
Description: Hospitalization because of SARS-CoV-2 infectionMeasure: Hospitalization Time: 2 month
Description: To describe clinical presentation of SARS-CoV-2 infection in patients with rheumatic diseasesMeasure: SARS-CoV-2 infection presentation Time: 1 month
Description: Proportion of patients admitted at the intensive care unitMeasure: Admission at the intensive care unit Time: 2 month
Description: Proportion of patients who required invasive mechanical ventilationMeasure: Invasive mechanical ventilation Time: 2 month
Description: Proportion of patients who had complications associated with COVID-19 infection and describe themMeasure: COVID-19 Complications Time: 2 month
Description: Proportion of patients fully or partially recovered after COVID-19 infection.Measure: Recovery rate Time: 2 month
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports